

Specimen Collected: 13-Jun-23 07:14

LG11 Ab IgG CBA w/Reflex to Titer, Serum	Received: 13-Jun-23 07:14	Report/Verified: 13-Jun-23 07:16
--	---------------------------	----------------------------------

Procedure	Result	Units	Reference Interval
LG11 Ab IgG CBA-IFA Screen, Serum	Detected * t1 i1		[<1:10]

LGL1 Ab IgG Titer by CBA-IFA, Ser	Received: 13-Jun-23 07:14	Report/Verified: 13-Jun-23 07:16
-----------------------------------	---------------------------	----------------------------------

Procedure	Result	Units	Reference Interval
LG11 Ab IgG CBA-IFA Titer, Serum	1:640 * i2		[<1:10]

Interpretive Text

t1: 13-Jun-23 07:14 (LG11 Ab IgG CBA-IFA Screen, Serum)
 LG11 Antibody, IgG is detected. Titer results to follow.

Test Information

i1: LG11 Ab IgG CBA-IFA Screen, Serum
 INTERPRETIVE INFORMATION: LG11 Ab IgG Screen by IFA, Serum

Leucine-rich, glioma-inactivated 1 protein (LG11) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LG11 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LG11 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LG11 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LG11 transfected cell lines for the detection and semiquantification of the LG11 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: LG11 Ab IgG CBA-IFA Titer, Serum
 INTERPRETIVE INFORMATION: LG11 Ab Titer IgG by IFA,
 Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-164-900089

Report Request ID: 17763697

Printed: 19-Jun-23 11:28

Page 1 of 1